Man Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.65M Buy
35,717
+32,447
+992% +$4.39M 0.01% 1073
2026
Q1
$418K Buy
+3,270
New +$408K ﹤0.01% 2128
2025
Q4
Sell
-33,329
Closed -$3.34M 2507
2025
Q3
$3.34M Buy
+33,329
New +$3M 0.01% 1233
2024
Q3
Sell
-6,190
Closed -$574K 2238
2024
Q2
$574K Buy
+6,190
New +$555K ﹤0.01% 1653
2024
Q1
Sell
-100,653
Closed -$8.99M 2297
2023
Q4
$8.99M Buy
+100,653
New +$7.47M 0.03% 703
2023
Q1
Sell
-11,396
Closed -$946K 2272
2022
Q4
$946K Buy
+11,396
New +$923K ﹤0.01% 1334
2018
Q3
Sell
-9,298
Closed -$885K 2243
2018
Q2
$885K Buy
+9,298
New +$855K ﹤0.01% 1644

Other funds holding XBI

Man Group's XBI Position: Q2 2026 in Review

Man Group increased its State Street SPDR S&P Biotech ETF (XBI) stake by 992% in Q2 2026, buying an estimated $4.39M and bringing the position to 35,717 shares worth $5.65M. The position accounts for 0.01% of the portfolio, ranked #1073.

Man Group first reported a position in XBI in Q2 2018 and has held it in 7 quarters since. The position peaked at $8.99M in Q4 2023. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Man Group held 35,717 shares of State Street SPDR S&P Biotech ETF worth $5.65M as of Q2 2026.
  • Man Group bought 32,447 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $4.39M.
  • State Street SPDR S&P Biotech ETF made up 0.01% of Man Group's portfolio in Q2 2026, its #1073 holding.
  • Man Group first reported a position in State Street SPDR S&P Biotech ETF in Q2 2018 and has held it in 7 quarters since.
  • Man Group's State Street SPDR S&P Biotech ETF position peaked at $8.99M in Q4 2023.
  • 933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.